The present invention generally relates to implantable medical devices, and more particularly to an implantable MRI-safe lead including a conductive jacket for dissipating or directing induced RF energy to a patient's body so as to reduce the generation of unwanted heat at the lead's stimulation electrodes.
Implantable medical devices are commonly used today to treat patients suffering from various ailments. Such implantable devices may be utilized to treat conditions such as pain, incontinence, sleep disorders, and movement disorders such as Parkinson's disease and epilepsy. Such therapies also appear promising in the treatment of a variety of psychological, emotional, and other physiological conditions.
One known type of implantable medical device, a neurostimulator, delivers mild electrical impulses to neural tissue using an electrical lead. For example, to treat pain, electrical impulses may be directed to specific sites. Such neurostimulation may result in effective pain relief and a reduction in the use of pain medications and/or repeat surgeries.
Typically, such devices are totally implantable and may be controlled by a physician or a patient through the use of an external programmer. Current systems generally include a non-rechargeable primary cell neurostimulator, a lead extension, and a stimulation lead, and the two main classes of systems may be referred to as: (1) Spinal Cord Stimulation (SCS) and (2) Deep Brain Stimulation (DBS).
An SCS stimulator may be implanted in the abdomen, upper buttock, or pectoral region of a patient and may include at least one extension running from the neurostimulator to the lead or leads which are placed somewhere along the spinal cord. Each of the leads (to be discussed in detail hereinbelow) currently contains from one to eight electrodes. Each extension (likewise to be discussed in detail below) is plugged into or connected to the neurostimulator at a proximal end thereof and is coupled to and interfaces with the lead or leads at a distal end of the extension or extensions.
The implanted neurostimulation system is configured to send mild electrical pulses to the spinal cord. These electrical pulses are delivered through the lead or leads to regions near the spinal cord or the nerve selected for stimulation. Each lead includes a small insulated wire coupled to an electrode at the distal end thereof through which the electrical stimulation is delivered. Typically, the lead also comprises a corresponding number of internal wires to provide separate electrical connection to each electrode such that each electrode may be selectively used to provide stimulation. Connection of the lead to an extension may be accomplished by means of a connector block including, for example, a series or combination of set-screws, ball-seals, etc. The leads are inserted into metal set screw blocks, and metal set screws are manipulated to press the contacts against the blocks to clamp them in place and provide an electrical connection between the lead wires and the blocks. Such an arrangement is shown in U.S. Pat. No. 5,458,629 issued Oct. 17, 1995 and entitled “Implantable Lead Ring Electrode and Method of Making”.
A DBS system comprises similar components (i.e. a neurostimulator, at least one extension, and at least one stimulation lead) and may be utilized to provide a variety of different types of electrical stimulation to reduce the occurrence or effects of Parkinson's disease, epileptic seizures, or other undesirable neurological events. In this case, the neurostimulator may be implanted into the pectoral region of the patient. The extension or extensions may extend up through the patient's neck, and the leads/electrodes are implanted in the brain. The leads may interface with the extension just above the ear on both sides of the patient. The distal end of the lead may contain from four to eight electrodes and, as was the case previously, the proximal end of the lead may connect to the distal end of the extension and held in place by set screws. The proximal portion of the extension plugs into the connector block of the neurostimulator.
Magnetic resonance imaging (MRI) is a relatively new and efficient technique that may be used in the diagnosis of many neurological disorders. It is an anatomical imaging tool which utilizes non-ionizing radiation (i.e. no x-rays or gamma rays) and provides a non-invasive method for the examination of internal structure and function. For example, MRI permits the study of the overall function of the heart in three dimensions significantly better than any other imaging method. Furthermore, imaging with tagging permits the non-invasive study of regional ventricular function.
MRI scanning is widely used in the diagnosis of diseases and injuries to the head. In fact, the MRI is now considered by many to be the preferred standard of care, and failure to prescribe MRI scanning can be considered questionable. For example, approximately sixteen million MRIs were performed in 1996 followed by approximately twenty million in the year 2000. It is projected that forty million MRIs will be performed in 2004.
In an MRI scanner, a magnet creates a strong magnetic field which aligns the protons of hydrogen atoms in the body and then exposes them to radio frequency (RF) energy from a transmitter portion of the scanner. This spins the various protons, and they produce a faint signal that is detected by a receiver portion of the scanner. A computer renders these signals into an image. During this process, three electromagnetic fields are produced; i.e. (1) a static magnetic field, (2) a gradient magnetic field, and (3) a radio frequency (RF) field. The main or static magnetic field may typically vary between 0.2 and 3.0 Tesla. A nominal value of 1.5 Tesla is approximately equal to 15,000 Gauss which is 30,000 times greater than the Earth's magnetic field of approximately 0.5 Gauss. The time varying or gradient magnetic field may have a maximum strength of approximately 40 milli-Tesla/meter at a frequency of 0-5 KHz. The RF may, for example, produce thousands of watts at frequencies of between 8-128 MHz. For example, up to 20,000 watts may be produced at 64 MHz and a static magnetic field of 1.5 Tesla; that is, 20 times more power than a typical toaster. Thus, questions have arisen regarding the potential risk associated with undesirable interaction between the MRI environment and the above-described neurostimulation systems; e.g. forces and torque on the implantable device within the MRI scanner caused by the static magnetic field, RF-induced heating, induced currents due to gradient magnetic fields, device damage, and image distortion. Of these interactions, the problems associated with induced RF currents in the leads are most deserving of attention since it has been found that the temperature in the leads can rise by as much as 25° Centigrade or higher in an MRI environment.
Accordingly, it would be desirable to provide an implantable medical device that may be safely operated in an MRI environment. It would be further desirable to provide an implantable medical device such as a SCS or DBS neurostimulation system that may be operated in an MRI environment without the generation of significant heat in the leads due to induced RF currents. It would be still further desirable to provide an MRI-safe, implantable lead that may be used in conjunction with known medical devices that dissipates or directs induced RF energy to a patient's body so as to reduce the generation of unwanted heat at the lead's stimulation electrodes. Other desirable features and characteristics of the present invention will become apparent from the subsequent detailed description of the invention and the appended claims, taken in conjunction with the accompanying drawings and this background of the invention.
According to an aspect of the invention, there is provided a medical lead configured to be implanted into a patient's body and having at least one distal stimulation electrode and at least one conductive filer electrically coupled to the distal stimulation electrode. A jacket is provided for housing the conductive filer and for providing a path distributed along at least a portion of the length of the lead for guiding induced RF energy from the filer to the patient's body.
The present invention will hereinafter be described in conjunction with the accompanying drawing, wherein like reference numerals denote like elements; and
The following detailed description of the invention is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Furthermore, there is no intention to be bound by any theory presented in the preceding background of the invention or the following detailed description of the invention. As appearing herein, the term ‘filer’ (also spelled “filar”) is intended in its broadest sense to denote a conductor of the type carried by an implantable medical lead.
Lead 24 is a small medical wire having special insulation thereon and includes one or more insulated electrical conductors each coupled at their proximal end to a connector and to contacts/electrodes 26 at its distal end. Some leads are designed to be inserted into a patient percutaneously (e.g. the Model 3487A Pisces—Quad® lead available from Medtronic, Inc.), and some are designed to be surgically implanted (e.g. Model 3998 Specify® lead, also available from Medtronic, Inc.). Lead 24 may contain a paddle at its distant end for housing electrodes 26; e.g. a Medtronic paddle having model number 3587A. Alternatively, electrodes 26 may comprise one or more ring contacts at the distal end of lead 24 as will be more fully described below.
While lead 24 is shown as being implanted in position to stimulate a specific site in spinal cord 30, it could also be positioned along the peripheral nerve or adjacent neural tissue ganglia or may be positioned to stimulate muscle tissue. Furthermore, electrodes/contacts 26 may be epidural, intrathecal or placed into spinal cord 30 itself. Effective spinal cord stimulation may be achieved by any of these lead placements. While the lead connector at proximal end of lead 24 may be coupled directly to neurostimulator 20, the lead connector is typically coupled to lead extension 22 as is shown in
A physician's programmer (not shown) utilizes telemetry to communicate with the implanted neurostimulator 20 to enable the physician to program and manage a patient's therapy and troubleshoot the system. A typical physician's programmer is available from Medtronic, Inc. and bears Model No. 7432. Similarly, a patient's programmer (also not shown) also uses telemetry to communicate with neurostimulator 20 so as to enable the patient to manage some aspects of their own therapy as defined by the physician. An example of a patient programmer is Model 7434 Itrel® 3 EZ Patient Programmer available from Medtronic, Inc.
Implantation of a neurostimulator typically begins with the implantation of at least one stimulation lead while the patient is under a local anesthetic. While there are many spinal cord lead designs utilized with a number of different implantation techniques, the largest distinction between leads revolves around how they are implanted. For example, surgical leads have been shown to be highly effective, but require a laminectomy for implantation. Percutaneous leads can be introduced through a needle, a much easier procedure. To simplify the following explanation, discussion will focus on percutaneous lead designs, although it will be understood by those skilled in the art that the inventive aspects are equally applicable to surgical leads. After the lead is implanted and positioned, the lead's distal end is typically anchored to minimize movement of the lead after implantation. The lead's proximal end is typically configured to connect to a lead extension 22. The proximal end of the lead extension is then connected to the neurostimulator 20.
The shaft of lead 46 preferably has a lumen 68 extending therethrough for receiving a stylet that adds a measure of rigidity during installation of the lead. The shaft preferably comprises a comparatively stiffer inner tubing member 70 (e.g. a polyamine, polyamide, high density polyethylene, polypropylene, polycarbonate or the like). Polyamide polymers are preferred. The shaft preferably includes a comparatively softer outer tubing member or jacket 72; e.g. silicon or other suitable elastomeric polymer. The conductive rings 71 are preferably of a biocompatible metal such as one selected from the noble group of metals, preferably palladium, platinum or gold and their alloys.
Leads of the type described above may be of the wound helix filer type or of the cabled filer type.
As can be seen, the lead filers 82 have a specific pitch and form a helix of a specific diameter. The helix diameter is relevant in determining the inductance of the lead. These filers themselves also have a specific diameter and are made of a specific material. The filer diameter, material, pitch and helix diameter are relevant in determining the impedance of the lead. In the case of a helically wound lead, the inductance contributes to a frequency dependent impedance.
The diameter of typical percutaneous leads is approximately 0.05 inch. This diameter is based upon the diameter of the needle utilized in the surgical procedure to deploy the lead and upon other clinical anatomical requirements. The length of such percutaneous SCS leads is based upon other clinical anatomical requirements. The length of such percutaneous SCS leads is typically 28 centimeters; however, other lengths are utilized to meet particular needs of specific patients and to accommodate special implant locations.
Lead length is an important factor in determining the suitability of using the lead in an MRI environment. For example, the greater length of the lead, the larger the effective loop area that is impacted by the electromagnetic field (i.e. the longer the lead, the larger the antenna). Furthermore, depending on the lead length, there can be standing wave effects that create areas of high current along the lead body. This can be problematic if the areas of high current are near the distal electrodes.
Compared to the helically wound lead, the cable lead has a smaller DC resistance because the length of the straight filer is less than that of a coiled filer and the impedance at high frequency is reduced because the inductance has been significantly reduced. It has been determined that the newer cabled filer designs tend to be more problematic in an MRI environment than do the wound helix filer designs. It should be noted that straight filers for cable leads sometimes comprise braided stranded wire that includes a number of smaller strands woven to make up each filer. This being the case, the number of strands could be varied to alter the impedance.
It has been discovered that high lead impedances at MRI operational frequencies can reduce the heating of an electrode during an MRI procedure. The high impedance acts as a choke for current flowing through the lead and increases real losses along the length of the lead. These two mechanisms reduce electrode heating. As previously alluded to, leads have been intentionally designed with low impedance to enhance system stimulation efficiency. Thus, the simplest way to increase the impedance of a lead is to increase its DC resistance.
For example, the resistance R of a lead filer is governed by the equation:
where R is the resistance, L is the length of the filer, σ is the conductivity, and a is the cross-sectional area. Decreasing the conductivity and/or the cross-sectional area of the filer will increase resistance proportionally. One typical lead utilizes a chromium-cobalt (non-cored MP35N) filer having a conductivity of 1.1×106 mhos/meter, a diameter of approximately 0.005 inch, and a length of approximately 100 centimeters. Using Equation (1), the resistance R of the lead is approximately twenty ohms. If the diameter were reduced to 0.002 inch, R could be increased to approximately 710 ohms (or approximately 126 ohms for a 28 centimeter lead).
Described below in connection with
In order to produce a lead jacket 120 that acts as a shunt at high frequency along the length thereof, the jacket material may be doped with a dielectric material such as carbon, talc, and minerals such as calcium carbonate, titanium dioxide, aluminum dioxide, sapphire, mica, and silica. Both pyrolitic and vitreous carbon would be suitable. In any case, the dopant should be biocompatible and preferably have a dielectric constant greater than five. Both the type and concentration of dopant is selected to obtain the desired frequency response in accordance with known techniques.
The dopant is represented graphically in
In accordance with a second exemplary embodiment of the inventive lead, the lead body or jacket may be provided with a plurality of pores 124 shown in
In another embodiment, the dopant and/or pores may be concentrated in a longitudinal path limited to one or more selected circumferential sectors as is shown in
Yet another embodiment of the present invention comprises a multi-layered jacket of the type shown in
where C is the capacitance, A is the area of the capacitor plates, d is the distance between the plates and ∈ is the dielectric constant of the material between them. It can be seen that the capacitance increases with area. Thus, the use of a flat ribbon coil will increase the capacitance. It should also be apparent that the smaller the distance between coil 126 and filers 98, the greater the capacitance between them. Thus, the lead may be constructed so as to place filers 98 closer to jacket 120. Additionally, the capacitance will increase if the jacket is made of a material having a higher dielectric constant.
If desired, jacket 120 may be provided with a plurality of pores 124 to expose coil 126 to body tissue. In addition, coil 126 may be placed on the inner surface of jacket 120 as is shown in
While at least one exemplary embodiment has been presented in the foregoing detailed description of the invention, it should be appreciated that a vast number of variations exist. For example, while the invention has been described in connection with neurostimulation systems, the invention is equally applicable to other lead assemblies (e.g. implantable cardiac leads) that may be adversely impacted in high frequency environments such as is encountered during an MRI scan. It should also be appreciated that the exemplary embodiment or exemplary embodiments are only examples, and are not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing an exemplary embodiment of the invention, it being understood that various changes may be made in the function and arrangement of elements described in an exemplary embodiment without departing from the scope of the invention as set forth in the appended claims.
This application claims the benefit of U.S. Provisional Application No. 60/557,991 filed Mar. 30, 2004.
Number | Name | Date | Kind |
---|---|---|---|
3788329 | Friedman | Jan 1974 | A |
3915174 | Preston | Oct 1975 | A |
4038990 | Thompson | Aug 1977 | A |
4220813 | Kyle | Sep 1980 | A |
4280507 | Rosenberg | Jul 1981 | A |
4320763 | Money | Mar 1982 | A |
4383225 | Mayer | May 1983 | A |
4628942 | Sweeney et al. | Dec 1986 | A |
4711027 | Harris | Dec 1987 | A |
4726379 | Altman et al. | Feb 1988 | A |
4852585 | Heath | Aug 1989 | A |
4920980 | Jackowski | May 1990 | A |
4947866 | Lessar et al. | Aug 1990 | A |
4951672 | Buchwald et al. | Aug 1990 | A |
4991583 | Silvian | Feb 1991 | A |
5012045 | Sato | Apr 1991 | A |
5018523 | Bach, Jr. et al. | May 1991 | A |
5020544 | Dahl et al. | Jun 1991 | A |
5020545 | Soukup | Jun 1991 | A |
5036862 | Pohndorf | Aug 1991 | A |
5040544 | Lessar et al. | Aug 1991 | A |
5063932 | Dahl et al. | Nov 1991 | A |
5197468 | Proctor et al. | Mar 1993 | A |
5217010 | Tsitlik et al. | Jun 1993 | A |
5246438 | Langberg | Sep 1993 | A |
5260128 | Ishii et al. | Nov 1993 | A |
5271417 | Swanson et al. | Dec 1993 | A |
5314459 | Swanson et al. | May 1994 | A |
5323776 | Blakeley et al. | Jun 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5349133 | Rogers | Sep 1994 | A |
5366496 | Dahl et al. | Nov 1994 | A |
5370644 | Langberg | Dec 1994 | A |
5374778 | Hashimoto et al. | Dec 1994 | A |
5417719 | Hull et al. | May 1995 | A |
5458629 | Baudino et al. | Oct 1995 | A |
5466252 | Soukup et al. | Nov 1995 | A |
5476496 | Strandberg et al. | Dec 1995 | A |
5504274 | McCabe et al. | Apr 1996 | A |
5514172 | Mueller | May 1996 | A |
5515848 | Corbett, III et al. | May 1996 | A |
5523578 | Herskovic | Jun 1996 | A |
5527348 | Winkler | Jun 1996 | A |
5591218 | Jacobson | Jan 1997 | A |
5594304 | Graber | Jan 1997 | A |
5609622 | Soukup et al. | Mar 1997 | A |
5629622 | Scampini | May 1997 | A |
5649965 | Pons et al. | Jul 1997 | A |
5662697 | Li et al. | Sep 1997 | A |
5676694 | Boser et al. | Oct 1997 | A |
5683435 | Truex et al. | Nov 1997 | A |
5697909 | Eggers et al. | Dec 1997 | A |
5697958 | Paul et al. | Dec 1997 | A |
5702437 | Baudino | Dec 1997 | A |
5722998 | Prutchi et al. | Mar 1998 | A |
5727552 | Ryan | Mar 1998 | A |
5751539 | Stevenson et al. | May 1998 | A |
5782241 | Felblinger et al. | Jul 1998 | A |
5814076 | Brownlee | Sep 1998 | A |
5827997 | Chung et al. | Oct 1998 | A |
5830136 | Delonzor et al. | Nov 1998 | A |
5842966 | Markoll | Dec 1998 | A |
5851226 | Skubitz et al. | Dec 1998 | A |
5905627 | Brendel et al. | May 1999 | A |
5954760 | Jarl | Sep 1999 | A |
5964705 | Truwit et al. | Oct 1999 | A |
5970429 | Martin | Oct 1999 | A |
6033408 | Gage et al. | Mar 2000 | A |
6101417 | Vogel et al. | Aug 2000 | A |
6195267 | MacDonald et al. | Feb 2001 | B1 |
6198972 | Hartlaub et al. | Mar 2001 | B1 |
6209764 | Hartlaub et al. | Apr 2001 | B1 |
6258071 | Brookes | Jul 2001 | B1 |
6265466 | Glatkowski | Jul 2001 | B1 |
6284971 | Atalar et al. | Sep 2001 | B1 |
6302740 | Holmstrom | Oct 2001 | B1 |
6348070 | Teissl et al. | Feb 2002 | B1 |
6424234 | Stevenson | Jul 2002 | B1 |
6471699 | Fleischman et al. | Oct 2002 | B1 |
6488704 | Connelly et al. | Dec 2002 | B1 |
6494916 | Babalola et al. | Dec 2002 | B1 |
6501991 | Honeck et al. | Dec 2002 | B1 |
6503648 | Wang | Jan 2003 | B1 |
6506972 | Wang | Jan 2003 | B1 |
6529774 | Greene | Mar 2003 | B1 |
6538191 | MacDonald | Mar 2003 | B1 |
6895280 | Meadows et al. | Jun 2003 | B2 |
6640137 | MacDonald | Oct 2003 | B2 |
6660116 | Wolf et al. | Dec 2003 | B2 |
6673999 | Wang et al. | Jan 2004 | B1 |
6675033 | Lardo et al. | Jan 2004 | B1 |
6689835 | Amarasekera et al. | Feb 2004 | B2 |
6695761 | Oschman et al. | Feb 2004 | B2 |
6708051 | Durousseau | Mar 2004 | B1 |
6711440 | Deal et al. | Mar 2004 | B2 |
6713671 | Wang et al. | Mar 2004 | B1 |
6718203 | Weiner et al. | Apr 2004 | B2 |
6718207 | Connelly | Apr 2004 | B2 |
6725092 | MacDonald et al. | Apr 2004 | B2 |
6741892 | Meadows et al. | May 2004 | B1 |
6750055 | Connelly et al. | Jun 2004 | B1 |
6757566 | Weiner et al. | Jun 2004 | B2 |
6760628 | Weiner et al. | Jul 2004 | B2 |
6763268 | MacDonald et al. | Jul 2004 | B2 |
6765144 | Wang et al. | Jul 2004 | B1 |
6768053 | Wang et al. | Jul 2004 | B1 |
6778856 | Connelly et al. | Aug 2004 | B2 |
6785736 | Connelly et al. | Sep 2004 | B1 |
6793642 | Connelly et al. | Sep 2004 | B2 |
6795730 | Connelly et al. | Sep 2004 | B2 |
6795736 | Connelly et al. | Sep 2004 | B2 |
6815609 | Wang et al. | Nov 2004 | B1 |
6844492 | Wang et al. | Jan 2005 | B1 |
6845267 | Harrison et al. | Jan 2005 | B2 |
6864418 | Wang et al. | Mar 2005 | B2 |
6872882 | Fritz | Mar 2005 | B2 |
6882519 | Uzawa et al. | Apr 2005 | B2 |
6901290 | Foster et al. | May 2005 | B2 |
6906256 | Wang | Jun 2005 | B1 |
6920361 | Williams | Jul 2005 | B2 |
6922590 | Whitehurst | Jul 2005 | B1 |
6930242 | Helfer | Aug 2005 | B1 |
6949929 | Gray et al. | Sep 2005 | B2 |
6971391 | Wang et al. | Dec 2005 | B1 |
6980865 | Wang et al. | Dec 2005 | B1 |
6999818 | Stevenson et al. | Feb 2006 | B2 |
6999821 | Jenney et al. | Feb 2006 | B2 |
7103413 | Swanson | Sep 2006 | B2 |
7118693 | Glatkowski et al. | Oct 2006 | B2 |
7123013 | Gray | Oct 2006 | B2 |
7162302 | Wang et al. | Jan 2007 | B2 |
7174219 | Wahlstrand et al. | Feb 2007 | B2 |
7233825 | Jorgenson et al. | Jun 2007 | B2 |
7282260 | LeGrande et al. | Oct 2007 | B2 |
7292894 | Belden | Nov 2007 | B2 |
7319901 | Dublin | Jan 2008 | B2 |
7389148 | Morgan | Jun 2008 | B1 |
7591831 | Parsonage et al. | Sep 2009 | B2 |
20020032468 | Hill et al. | Mar 2002 | A1 |
20020038135 | Connelly et al. | Mar 2002 | A1 |
20020058978 | Sass | May 2002 | A1 |
20020082673 | Benz et al. | Jun 2002 | A1 |
20020116028 | Greatbatch et al. | Aug 2002 | A1 |
20020116029 | Miller et al. | Aug 2002 | A1 |
20020116033 | Greatbatch et al. | Aug 2002 | A1 |
20020116034 | Miller et al. | Aug 2002 | A1 |
20020128689 | Connelly et al. | Sep 2002 | A1 |
20020128691 | Connelly | Sep 2002 | A1 |
20020133086 | Connelly et al. | Sep 2002 | A1 |
20020133199 | MacDonald et al. | Sep 2002 | A1 |
20020133200 | Weiner et al. | Sep 2002 | A1 |
20020133201 | Connelly et al. | Sep 2002 | A1 |
20020133202 | Connelly et al. | Sep 2002 | A1 |
20020133208 | Connelly | Sep 2002 | A1 |
20020133211 | Weiner et al. | Sep 2002 | A1 |
20020133216 | Connelly et al. | Sep 2002 | A1 |
20020138102 | Weiner et al. | Sep 2002 | A1 |
20020138107 | Weiner et al. | Sep 2002 | A1 |
20020138108 | Weiner et al. | Sep 2002 | A1 |
20020138110 | Connelly et al. | Sep 2002 | A1 |
20020138112 | Connelly et al. | Sep 2002 | A1 |
20020183740 | Edwards et al. | Dec 2002 | A1 |
20020183822 | Bodner | Dec 2002 | A1 |
20020188345 | Pacetti | Dec 2002 | A1 |
20030009207 | Paspa et al. | Jan 2003 | A1 |
20030014080 | Baudino | Jan 2003 | A1 |
20030036776 | Foster et al. | Feb 2003 | A1 |
20030044623 | Sakurai et al. | Mar 2003 | A1 |
20030083570 | Cho et al. | May 2003 | A1 |
20030083723 | Wilkinson et al. | May 2003 | A1 |
20030083726 | Zeijlemaker et al. | May 2003 | A1 |
20030109901 | Greatbatch | Jun 2003 | A1 |
20030117787 | Nakauchi | Jun 2003 | A1 |
20030120148 | Pacetti | Jun 2003 | A1 |
20030120197 | Kaneko et al. | Jun 2003 | A1 |
20030135114 | Pacetti et al. | Jul 2003 | A1 |
20030140931 | Zeijlemaker et al. | Jul 2003 | A1 |
20030144704 | Terry et al. | Jul 2003 | A1 |
20030144705 | Funke | Jul 2003 | A1 |
20030144716 | Reinke et al. | Jul 2003 | A1 |
20030144717 | Hagele | Jul 2003 | A1 |
20030144718 | Zeijlemaker | Jul 2003 | A1 |
20030144719 | Zeijlemaker | Jul 2003 | A1 |
20030144720 | Villaseca et al. | Jul 2003 | A1 |
20030144721 | Villaseca et al. | Jul 2003 | A1 |
20030204217 | Greatbatch | Oct 2003 | A1 |
20030225331 | Diederich et al. | Dec 2003 | A1 |
20040020674 | McFadden et al. | Feb 2004 | A1 |
20040068307 | Goble | Apr 2004 | A1 |
20040173368 | Dickson | Sep 2004 | A1 |
20040199069 | Connelly et al. | Oct 2004 | A1 |
20040251042 | Weiner et al. | Dec 2004 | A1 |
20040263174 | Gray et al. | Dec 2004 | A1 |
20050065587 | Gryzwa | Mar 2005 | A1 |
20050070972 | Wahlstrand | Mar 2005 | A1 |
20050080471 | Chitre et al. | Apr 2005 | A1 |
20050113876 | Weiner | May 2005 | A1 |
20050159661 | Connelly et al. | Jul 2005 | A1 |
20050182471 | Wang | Aug 2005 | A1 |
20050222642 | Przybyszewski | Oct 2005 | A1 |
20050222656 | Wahlstrand | Oct 2005 | A1 |
20050222658 | Hoegh et al. | Oct 2005 | A1 |
20050222659 | Olsen | Oct 2005 | A1 |
20060155270 | Hancock | Jul 2006 | A1 |
20060200218 | Wahlstrand | Sep 2006 | A1 |
20060247747 | Olsen | Nov 2006 | A1 |
20060247748 | Wahlstrand | Nov 2006 | A1 |
20070185556 | Williams | Aug 2007 | A1 |
20080195186 | Li | Aug 2008 | A1 |
20080195187 | Li | Aug 2008 | A1 |
20080269863 | Alexander | Oct 2008 | A1 |
Number | Date | Country |
---|---|---|
0624383 | Nov 1994 | EP |
0 713 714 | May 1996 | EP |
0 760 196 | Mar 1997 | EP |
1 273 922 | Jan 2003 | EP |
1424095 | Jun 2004 | EP |
1466576 | Oct 2004 | EP |
07255863 | Oct 1995 | JP |
11086641 | Mar 1999 | JP |
WO9628951 | Sep 1996 | WO |
WO 9741923 | Nov 1997 | WO |
WO 9910035 | Mar 1999 | WO |
WO 9919020 | Apr 1999 | WO |
WO 9960370 | Nov 1999 | WO |
WO 0027279 | May 2000 | WO |
WO0180940 | Nov 2001 | WO |
WO02083236 | Oct 2002 | WO |
WO 03037429 | May 2003 | WO |
WO03061755 | Jul 2003 | WO |
WO03063946 | Aug 2003 | WO |
WO 03063948 | Aug 2003 | WO |
WO 03063952 | Aug 2003 | WO |
WO 03063953 | Aug 2003 | WO |
WO03063954 | Aug 2003 | WO |
WO 03063955 | Aug 2003 | WO |
WO 03063956 | Aug 2003 | WO |
WO 03063957 | Aug 2003 | WO |
WO 03075797 | Sep 2003 | WO |
WO 03092326 | Nov 2003 | WO |
WO 03095022 | Nov 2003 | WO |
WO 2004052448 | Jun 2004 | WO |
WO 2004073040 | Aug 2004 | WO |
WO2005030322 | Apr 2005 | WO |
WO2005102444 | Nov 2005 | WO |
WO2005102445 | Nov 2005 | WO |
WO2005102446 | Nov 2005 | WO |
WO2005102447 | Nov 2005 | WO |
WO2006031317 | Mar 2006 | WO |
WO2006093685 | Sep 2006 | WO |
WO2006093686 | Sep 2006 | WO |
WO2006118640 | Nov 2006 | WO |
WO2006118641 | Nov 2006 | WO |
WO2008100839 | Aug 2008 | WO |
WO2008100840 | Aug 2008 | WO |
WO2008134196 | Nov 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20050222657 A1 | Oct 2005 | US |
Number | Date | Country | |
---|---|---|---|
60557991 | Mar 2004 | US |